**Table 1. Changes of body mass index over time depending on insulin treatment before the administration of iGlarLixi**

|  |  |  |  |
| --- | --- | --- | --- |
| **Parameter** | **Total sample (n = 95)** | **Patients on insulin treatment at baseline (n = 48)** | **Non-insulin treated patients at baseline (n = 47)** |
| Median BMI\*: |
| Before the administration of iGlarLixi | 35.1 [31.2; 40.3] | 35.7 [31.6; 40.4] | 34.7 [30.1; 39.3] |
| After treatment with iGlarLixi | 34.7 [30.5; 38.1]p = 0.011 | 34.9 [31.4; 38.0]p = 0.007 | 33.4 [29.1; 38.2]p = 0.274 |
| Patient numbers, N (%)\*\*: |
| BMI decreased | 46 (48.4) | 24 (50.0) | 22 (46.0) |
| No changes in BMI | 23 (24.2) | 14 (29.0) | 9 (19.2) |
| BMI increased | 26 (27.4) | 10 (20.8) | 16 (34.0) |

BMI, body mass index, iGlarLixi, a fixed combination on insulin glargine 100 U/mL and lixisenatide

\* Significance of the BMI differences within the group between the baseline and on treatment with iGlarLixi values (Wilcoxon test)

\*\* Absolute patient numbers and the proportions (٪) in the group

**Table 2. Changes of glycated hemoglobin levels over time depending on the changes of body mass index after the administration of iGlarLixi and depending on baseline insulin treatment**

|  |  |  |  |
| --- | --- | --- | --- |
| **HbA1c, %, median** | **Patients on insulin treatment at baseline (n = 48)** |  | **Non-insulin treated patients at baseline (n = 47)** |
| **baseline** | **At 6 months and above** | **baseline** | **At 6 months and above** |
| Patients with a BMI decrease under treatment with iGlarLixi (n = 46) | 7.4 [6.9; 8.4] | 7.2 [6.6; 7.8] | 8.0 [7.2; 9.4] | 7.1 [6.5; 8.0] |
| n = 24, p = 0.059 | n = 22, p < 0.001 |
| Patients with no changes in BMI under treatment with iGlarLixi (n = 23) | 7.9 [7.1; 9.3] | 7.0 [6.2; 8.6] | 8.2 [7.3; 9.1] | 7.2 [6.4; 7.7] |
| n = 14, p = 0.055 | n = 9, p = 0.007 |
| Patients with a BMI increase under treatment with iGlarLixi (n = 26) | 7.4 [6.8; 9.7] | 6.8 [6.0; 7.5] | 7.6 [6.7; 8.7] | 6.8 [6.3; 7.4] |
| n = 10, p = 0.047 | n = 16, p = 0.013 |
| Total sample (n = 95) | 7.5 [6.9; 9.0] | 7.1 [6.5; 7.8] | 7.9 [7.0; 8.9] | 7.0 [6.5; 7.8] |
| p = 0.001 | p < 0.001 |

BMI, body mass index; HbA1c, glycated hemoglobin; iGlarLixi, a fixed combination on insulin glargine 100 U/mL and lixisenatide

The significance of the difference is shown for the comparison of changes in HbA1c over time within the group between the values before and after treatment with iGlarLixi (Wilcoxon test)